专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100135993A1 METHOD OF TREATING MALIGNANT MESOTHELIOMA 审中-公开
标题翻译：治疗恶性肿瘤的方法
公开(公告)号：US20100135993A1
公开(公告)日：2010-06-03
申请号：US12450223
申请日：2008-03-14
申请人： Chikao Morimoto , Kei Ohnuma , Teruo Inamoto
发明人： Chikao Morimoto , Kei Ohnuma , Teruo Inamoto
IPC分类号： A61K39/395 , A61K31/7105 , C12N5/071 , G01N33/53 , A61P35/00
CPC分类号： A61K39/3955 , A61K31/7088 , A61K35/12 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/732 , C12N15/1138 , C12N2310/14
摘要： The present invention relates to a therapeutic agent for malignant mesothelioma comprising a substance which inhibits binding of CD26 to extracellular matrix such as an siRNA targeting CD26 cDNA or an anti-CD26 antibody. The present invention also relates to a method of treating malignant mesothelioma, which comprises administering the substance to a patient in need thereof.
摘要翻译：本发明涉及恶性间皮瘤治疗剂，其包括抑制CD26与细胞外基质如靶向CD26 cDNA或抗CD26抗体的siRNA结合的物质。本发明还涉及一种治疗恶性间皮瘤的方法，其包括向有需要的患者施用该物质。

2. 发明申请

US20090136523A1 ANTI-CD26 ANTIBODIES AND METHODS OF USE THEREOF 有权
标题翻译：抗CD26抗体及其使用方法
公开(公告)号：US20090136523A1
公开(公告)日：2009-05-28
申请号：US12263919
申请日：2008-11-03
申请人： Teikichi Aoyagi , Peter Peizhi Luo , Pingyu Zhong , Mark Hsieh , Yan Li , Kevin Caili Wang , Chikao Morimoto
发明人： Teikichi Aoyagi , Peter Peizhi Luo , Pingyu Zhong , Mark Hsieh , Yan Li , Kevin Caili Wang , Chikao Morimoto
IPC分类号： A61K39/395 , C07K16/18 , C12N15/11 , C12N15/00 , C12N5/06
CPC分类号： C07K16/2896 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/92 , G01N33/574 , G01N2333/70596 , G01N2500/00 , Y02A50/473
摘要： The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.
摘要翻译：本发明提供新的抗CD26抗体和其它相关多肽，以及编码抗体和多肽的新型多核苷酸。本发明还提供了制备抗体和多肽的方法。进一步提供包含抗体或多肽的组合物和细胞。还提供了使用抗体和/或多肽的方法，例如抑制细胞增殖和治疗与CD26相关的病症。

3. 发明申请

US20050123524A1 Pharmaceutical compositions and methods for treating neuronal damages and neurodegenerative diseases 审中-公开
标题翻译：用于治疗神经损伤和神经变性疾病的药物组合物和方法
公开(公告)号：US20050123524A1
公开(公告)日：2005-06-09
申请号：US10985036
申请日：2004-11-10
申请人： Chikao Morimoto , Takahiro Sasaki
发明人： Chikao Morimoto , Takahiro Sasaki
IPC分类号： C12N15/09 , A61K35/30 , A61K38/00 , A61K38/17 , A61K38/43 , A61K38/45 , A61K48/00 , A61P9/10 , A61P25/00 , A61P25/14 , A61P25/18 , A61P25/28 , C12N5/0793 , C12N5/10
CPC分类号： C12N5/0619 , A61K35/30 , A61K38/1709 , A61K38/45 , A61K48/00 , C12N2501/13 , C12N2501/998 , A61K2300/00
摘要： Pharmaceutical compositions comprising Nedd9 protein are provided. The pharmaceutical compositions may further comprise FAK protein. These compositions can be used for the treatment of neuronal damages and neurodegenerative diseases. Methods for treating neuronal damages or neurodegenerative diseases are also provided. The methods comprise administering a composition comprising Nedd9 protein. Furthermore, methods for differentiating neuronal cells are provided. The methods comprise introducing a gene encoding Nedd9 protein into neuronal cells and allowing the expression of the gene in the cells.
摘要翻译：提供了包含Nedd9蛋白质的药物组合物。药物组合物还可以包含FAK蛋白。这些组合物可用于治疗神经损伤和神经变性疾病。还提供了治疗神经损伤或神经变性疾病的方法。所述方法包括施用包含Nedd9蛋白的组合物。此外，提供了用于区分神经元细胞的方法。所述方法包括将编码Nedd9蛋白的基因导入神经元细胞并允许基因在细胞中的表达。

4. 发明授权

US06265551B1 Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof 失效
标题翻译：在人血清，抗体中发现的二肽基肽酶IV（CD26）的形式及其用途
公开(公告)号：US06265551B1
公开(公告)日：2001-07-24
申请号：US08657339
申请日：1996-06-03
申请人： Jonathan S. Duke-Cohan , Chikao Morimoto , Stuart F. Schlossman
发明人： Jonathan S. Duke-Cohan , Chikao Morimoto , Stuart F. Schlossman
IPC分类号： C07K1600
CPC分类号： G01N33/573 , A61K38/00 , C07K16/40 , C12N9/48 , Y10S435/975
摘要： A circulating, soluble form of DPPIV/CD26 isolated from human serum is disclosed. The serum form shares similar enzymatic and antigenic properties with the ubiquitous membrane form. However, in several biochemical aspects there are distinct differences. In particular, the circulating serum form has a molecular weight of 175 kDa (in contrast to the 105 kDa molecular weight of the membrane form), and it does not bind Adenosine Deaminase Type-1. Nevertheless, the circulating form expresses functional dipeptidylpeptidase IV activity and retains the ability to costimulate the T lymphocyte response to recall antigen. Circulating DPPIV has been determined to be the soluble form of a 175 kDa DPPIV CD26-related molecule rapidly expressed on the surface of activated T cells, prior to the expression of 105 kDa CD26. Although 105 kDa membrane type CD26 may be found in the serum in small amounts, the majority of serum DPPIV activity is provided by a novel peptidase structurally distinct from 105 kDa CD26/DPPIV. Polyclonal and monoclonal antibodies capable of distinguishing the 175 kDa form from the 105 kDa form are also disclosed.
摘要翻译：公开了从人血清中分离的循环的可溶形式的DPPIV / CD26。血清形式与普遍存在的膜形式具有相似的酶和抗原性质。然而，在几个生化方面有明显的差异。特别地，循环血清形式的分子量为175kDa（与膜形式的105kDa分子量相反），并且不结合腺苷脱氨酶1型。然而，循环形式表达功能性二肽基肽酶IV活性，并保留共同刺激T淋巴细胞回忆抗原的能力。循环DPPIV已被确定为在表达105kDa CD26之前在激活的T细胞表面上快速表达的175kDa DPPIV CD26相关分子的可溶形式。尽管可以少量在血清中发现105kDa膜型CD26，但大部分血清DPPIV活性由与105kDa CD26 / DPPIV结构不同的新型肽酶提供。还公开了能够区分175kDa形式与105kDa形式的多克隆和单克隆抗体。

5. 发明授权

US4649106A Distinguishing subsets of human cells 失效
标题翻译：区分人体细胞亚群
公开(公告)号：US4649106A
公开(公告)日：1987-03-10
申请号：US616284
申请日：1984-06-01
申请人： Stuart F. Schlossman , Chikao Morimoto
发明人： Stuart F. Schlossman , Chikao Morimoto
IPC分类号： G01N33/50 , A61K39/00 , C07K14/005 , C07K14/195 , C07K16/00 , C07K16/28 , C12N5/00 , C12N5/10 , C12N15/00 , C12N15/02 , C12P21/00 , C12P21/08 , C12Q1/00 , C12R1/91 , G01N33/53 , G01N33/577 , G01N33/554
CPC分类号： C07K16/289 , Y10S530/868
摘要： A method of distinguishing subsets within a plurality of human cells including producing a monoclonal antibody to a non-human primate cell, contacting the monoclonal antibody with the human cells, and distinguishing the subsets on the basis of different degrees of reactivity with the monoclonal antibody.
摘要翻译：区分多个人细胞内的子集的方法，包括产生单克隆抗体至非人灵长类动物细胞，使单克隆抗体与人细胞接触，并根据与单克隆抗体的不同程度的反应性区分亚群。

6. 发明申请

US20140004103A1 Method of treating malignant mesothelioma 有权
公开(公告)号：US20140004103A1
公开(公告)日：2014-01-02
申请号：US13385206
申请日：2012-02-07
申请人： Chikao Morimoto , Kei Ohnuma , Teruo Inamoto
发明人： Chikao Morimoto , Kei Ohnuma , Teruo Inamoto
IPC分类号： C07K16/40 , A61K39/395 , A61K35/12
CPC分类号： A61K39/3955 , A61K31/7088 , A61K35/12 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/732 , C12N15/1138 , C12N2310/14
摘要： The present invention relates to a therapeutic agent for malignant mesothelioma comprising a substance which inhibits binding of CD26 to extracellular matrix such as an siRNA targeting CD26 cDNA or an anti-CD26 antibody. The present invention also relates to a method of treating malignant mesothelioma, which comprises administering the substance to a patient in need thereof.

7. 发明授权

US07704686B2 Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof 失效
标题翻译：鉴定免疫调节剂，免疫调节剂及其用途的方法
公开(公告)号：US07704686B2
公开(公告)日：2010-04-27
申请号：US10584837
申请日：2004-12-28
申请人： Chikao Morimoto , Kei Ohnuma
发明人： Chikao Morimoto , Kei Ohnuma
IPC分类号： A61K48/00
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/14 , G01N33/505 , G01N33/9493
摘要： The present invention provides methods of identifying a substance that down-regulates or up-regulates an immune response and kits used for the identification methods. A method of this invention comprises detecting a substance that inhibits or enhances the interaction between CD26 and caveolin-1. Another method comprises detecting a substance that inhibits or enhances the interaction between caveolin-1 and Tollip. Still another method comprises detecting a substance that inhibits or enhances the interaction among caveolin-1, Tollip, and IRAK-1. The present invention also relates to immunoregulatory agents comprising a substance that down-regulates an immune response, such as siRNA against caveolin-1 or Tollip. The invention further provides immunoregulatory agents comprising a substance that up-regulates an immune response. These agents are useful for treating inflammatory diseases, autoimmune diseases, or other immune-mediated disorders.
摘要翻译：本发明提供鉴定下调或上调免疫应答的物质的方法和用于鉴定方法的试剂盒的方法。本发明的方法包括检测抑制或增强CD26和小窝蛋白-1之间相互作用的物质。另一种方法包括检测抑制或增强窖1与Tollip之间相互作用的物质。另一种方法包括检测抑制或增强窖1，Tollip和IRAK-1之间相互作用的物质。本发明还涉及免疫调节剂，其包含下调免疫应答的物质，例如针对窖1或Tollip的siRNA。本发明进一步提供了包含上调免疫应答的物质的免疫调节剂。这些药剂可用于治疗炎性疾病，自身免疫疾病或其他免疫介导的疾病。

8. 发明授权

US07658923B2 Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26 有权
标题翻译：抗CD26单克隆抗体作为与表达CD26的细胞相关疾病的治疗
公开(公告)号：US07658923B2
公开(公告)日：2010-02-09
申请号：US11676164
申请日：2007-02-16
申请人： Nam Hoang Dang , Chikao Morimoto , Stuart Schlossman
发明人： Nam Hoang Dang , Chikao Morimoto , Stuart Schlossman
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , A61K38/19 , A61K2039/505 , C07K16/2896 , A61K2300/00
摘要： Therapeutic methods comprising administering anti-CD26 antibodies for the prevention and treatment of cancers and immune diseases associated with expressing CD26 are provided. The invention describes various types of anti-CD26 antibodies and modes of administration.
摘要翻译：提供了包括施用用于预防和治疗与表达CD26相关的癌症和免疫疾病的抗CD26抗体的治疗方法。本发明描述了各种类型的抗CD26抗体和给药方式。

9. 发明申请

US20070105771A1 Anti-CD26 antibodies and methods of use thereof 有权
标题翻译：抗CD26抗体及其使用方法
公开(公告)号：US20070105771A1
公开(公告)日：2007-05-10
申请号：US11492498
申请日：2006-07-24
申请人： Teikichi Aoyagi , Peter Luo , Pingyu Zhong , Mark Hsieh , Yan Li , Kevin Wang , Chikao Morimoto
发明人： Teikichi Aoyagi , Peter Luo , Pingyu Zhong , Mark Hsieh , Yan Li , Kevin Wang , Chikao Morimoto
IPC分类号： A61K38/17 , C12Q1/68 , G01N33/53 , C07H21/04 , C12P21/06 , C07K14/74 , C07K16/30 , C12N1/21
CPC分类号： C07K16/2896 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/92 , G01N33/574 , G01N2333/70596 , G01N2500/00 , Y02A50/473
摘要： The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.
摘要翻译：本发明提供新的抗CD26抗体和其它相关多肽，以及编码抗体和多肽的新型多核苷酸。本发明还提供了制备抗体和多肽的方法。进一步提供包含抗体或多肽的组合物和细胞。还提供了使用抗体和/或多肽的方法，例如抑制细胞增殖和治疗与CD26相关的病症。

10. 发明授权

US07198788B2 Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26. 有权
标题翻译：抗CD26单克隆抗体作为与表达CD26的细胞相关疾病的治疗。
公开(公告)号：US07198788B2
公开(公告)日：2007-04-03
申请号：US10143553
申请日：2002-05-10
申请人： Nam Hoang Dang , Chikao Morimoto , Stuart Schlossman
发明人： Nam Hoang Dang , Chikao Morimoto , Stuart Schlossman
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , A61K38/19 , A61K2039/505 , C07K16/2896 , A61K2300/00
摘要： Therapeutic methods comprising administering anti-CD26 antibodies for the prevention and treatment of cancers and immune diseases associated with expressing CD26 are provided. The invention describes various types of anti-CD26 antibodies and modes of administration.
摘要翻译：提供了包括施用用于预防和治疗与表达CD26相关的癌症和免疫疾病的抗CD26抗体的治疗方法。本发明描述了各种类型的抗CD26抗体和给药方式。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式